Jefferies Group assumed coverage on shares of China Biologic Products Inc. (NASDAQ:CBPO) in a report released on Thursday, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $52.00 price objective on the stock. China Biologic Products Inc. (NASDAQ:CBPO) net profit margin is 33.90% and weekly performance is 4.64%. On last trading day company shares ended up $48.06. Analysts mean target price for the company is $51.00. China Biologic Products Inc. (NASDAQ:CBPO) distance from 50-day simple moving average (SMA50) is 20.66%.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Henry Morgan sold 17,940 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $27.00, for a total value of $484,380.00. Following the transaction, the director now directly owns 17,193 shares in the company, valued at approximately $464,211. BioSpecifics Technologies Corp. (NASDAQ:BSTC) shares advanced 2.05% in last trading session and ended the day on $27.84. BSTC return on assets is 17.90%.BioSpecifics Technologies Corp. (NASDAQ:BSTC) quarterly performance is 5.82%.
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced that company management will present at Jefferies Gene Therapy Summit on Monday, June 16, 2014 in Boston. Sue Washer, President and CEO will provide a corporate overview discussing the company’s lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). In addition, Ms. Washer will participate in an ophthalmology panel Q&A hosted by Dr. Jeffery Heier, Vitreoretinal Specialist at Ophthalmic Consultants of Boston. Applied Genetic Technologies Corp (NASDAQ:AGTC) shares moved down -4.90% in last trading session and was closed at $24.05, while trading in range of $21.66 – $26.81. Applied Genetic Technologies Corp (NASDAQ:AGTC) year to date (YTD) performance is 62.94%.
Vital Therapies Inc. (NASDAQ:VTL) on 5 June announced net loss for the quarter was $13.8 million with a per-share loss of $24.49, versus estimates of $9.4 million and $0.57, respectively; the discrepancy in loss per share is attributed to our estimate for weighted-average number of shares of 16.6 million for the quarter, compared to the 564,200 shares reported by the company. Vital Therapies Inc. (NASDAQ:VTL) ended the last trading day at $28.66. Company weekly volatility is calculated as 26.56%. Vital Therapies Inc. (NASDAQ:VTL) showed a positive weekly performance of 104.57%.
Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) weekly performance is 25.22%. On last trading day company shares ended up $17.43. Analysts mean target price for the company is $23.00. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) distance from 50-day simple moving average (SMA50) is 52.46%.